Aethlon Medical Inc. has announced preliminary observations from its ongoing oncology clinical trial in Australia evaluating the Hemopurifier®, a therapeutic device designed for patients with cancer not responding to anti-PD-1 therapy. The study is focused on safety, feasibility, and dose-finding. Early data from the initial patient cohort indicate changes in extracellular vesicles, microRNAs, and lymphocyte counts following a single Hemopurifier treatment. The company emphasized that these findings are based on a small number of patients and are limited to descriptive statistics without formal statistical analysis. Aethlon Medical noted that additional data from subsequent cohorts will be required to determine reproducibility and potential dose response. The company stated that no conclusions regarding clinical efficacy or safety can be drawn from these early observations, and further research in larger trials will be necessary. The results have been shared as early observations and have not yet been presented as final outcomes.